[go: up one dir, main page]

MX2024008629A - Derivados del azaindol y su uso como inhibidores de la erk-cinasa. - Google Patents

Derivados del azaindol y su uso como inhibidores de la erk-cinasa.

Info

Publication number
MX2024008629A
MX2024008629A MX2024008629A MX2024008629A MX2024008629A MX 2024008629 A MX2024008629 A MX 2024008629A MX 2024008629 A MX2024008629 A MX 2024008629A MX 2024008629 A MX2024008629 A MX 2024008629A MX 2024008629 A MX2024008629 A MX 2024008629A
Authority
MX
Mexico
Prior art keywords
erk
kinase inhibitors
azaindol
derivatives
azaindol derivatives
Prior art date
Application number
MX2024008629A
Other languages
English (en)
Inventor
Cédric Bories
Loïc Mathieu
Jean-François Guichou
Muriel Gelin
Aurélien Biechy
Original Assignee
Agv Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agv Discovery filed Critical Agv Discovery
Publication of MX2024008629A publication Critical patent/MX2024008629A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula (I): (ver Fórmula) (I) o una de sus sales farmacéuticamente aceptables, especialmente para su uso como inhibidores de la actividad cinasa ERK, en particular de la actividad ERK2.
MX2024008629A 2022-01-14 2023-01-13 Derivados del azaindol y su uso como inhibidores de la erk-cinasa. MX2024008629A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22305031.1A EP4212531A1 (en) 2022-01-14 2022-01-14 Azaindole derivatives and their use as erk kinase inhibitors
PCT/EP2023/050692 WO2023135233A1 (en) 2022-01-14 2023-01-13 Azaindole derivatives and their use as erk kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2024008629A true MX2024008629A (es) 2024-08-19

Family

ID=80445694

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008629A MX2024008629A (es) 2022-01-14 2023-01-13 Derivados del azaindol y su uso como inhibidores de la erk-cinasa.

Country Status (14)

Country Link
US (2) US11827637B2 (es)
EP (2) EP4212531A1 (es)
JP (1) JP2025502377A (es)
KR (1) KR20240134887A (es)
CN (1) CN118541370A (es)
AR (1) AR128267A1 (es)
AU (1) AU2023207276A1 (es)
CA (1) CA3242894A1 (es)
CL (1) CL2024002070A1 (es)
CO (1) CO2024008809A2 (es)
IL (1) IL314199A (es)
MX (1) MX2024008629A (es)
TW (1) TW202334147A (es)
WO (1) WO2023135233A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
WO2025012389A1 (en) * 2023-07-12 2025-01-16 Agv Discovery Salts of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5- morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one, their preparation and their use as erk kinase inhibitors
WO2025012357A1 (en) * 2023-07-12 2025-01-16 Ipsen Pharma Fluorinated azaindole derivatives and their use as erk kinase inhibitors
AU2024287893A1 (en) * 2023-07-12 2026-01-08 Agv Discovery Crystalline form of (s)-1-(1-(3-chlorophenyl)-2- (dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3- b]pyridin-3-yl)pyridin-2(1h)-one, its preparation and its use as erk kinase inhibitor
EP4588918A1 (en) 2024-01-18 2025-07-23 AGV Discovery Synthesis of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)- 4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
ES2897422T3 (es) 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN100396678C (zh) 2004-11-16 2008-06-25 财团法人工业技术研究院 1-苯甲基-3-(5’-羟甲基-2’-呋喃基)吲唑的吲哚类似物的合成及用途
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
BRPI0713187A2 (pt) 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
EP2102189B1 (en) 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
WO2012094313A1 (en) 2011-01-04 2012-07-12 Kinentia Biosciences Llc Pyrazole derivatives as erk inhibitors
EP2739143B1 (en) 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
CN104755478B (zh) 2012-10-16 2017-10-10 霍夫曼-拉罗奇有限公司 丝氨酸/苏氨酸激酶抑制剂
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
EP3247353A4 (en) 2015-01-23 2018-07-04 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
EP3170822A1 (en) * 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
SG11201903938XA (en) 2016-12-09 2019-05-30 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
BR112021009430A2 (pt) * 2018-11-16 2021-08-17 California Institute Of Technology inibidores de erk e usos dos mesmos
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors

Also Published As

Publication number Publication date
KR20240134887A (ko) 2024-09-10
US11827637B2 (en) 2023-11-28
EP4212531A1 (en) 2023-07-19
AR128267A1 (es) 2024-04-10
US12421231B2 (en) 2025-09-23
TW202334147A (zh) 2023-09-01
AU2023207276A1 (en) 2024-08-01
CA3242894A1 (en) 2025-02-28
CO2024008809A2 (es) 2024-08-08
CL2024002070A1 (es) 2024-11-29
JP2025502377A (ja) 2025-01-24
US20230227451A1 (en) 2023-07-20
US20240308997A1 (en) 2024-09-19
CN118541370A (zh) 2024-08-23
EP4463453A1 (en) 2024-11-20
WO2023135233A1 (en) 2023-07-20
IL314199A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
MX2024008629A (es) Derivados del azaindol y su uso como inhibidores de la erk-cinasa.
CO2022003782A2 (es) Inhibidores de kras g12d
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
AR119207A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
JOP20220008A1 (ar) مثبطات parp1
GEAP202416075A (en) New macrocyclic lrrk2 kinase inhibitors
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
ECSP10010272A (es) Derivados bis-(sulfonilamino) para uso en terapia
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
MX382166B (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos.
BR112015022993A8 (pt) inibidores de jak2 e alk2 e métodos para sua utilização.
MX2017013797A (es) Inhibidor de janus quinasa.
MX391410B (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
UY36152A (es) Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo
UY37028A (es) Compuestos inhibidores de prostaglandina d sintasa ematopoyética (h-pgds
UY32585A (es) Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa
CO2022010878A2 (es) Compuestos heterocíclicos novedosos útiles como inhibidores selectivos de aurora a
CR11433A (es) Inhibidores de quinasa c-fms
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
BR112022002222A2 (pt) Derivados de quinolina como inibidores de proteínas quinases
MX2024011130A (es) Inhibidor de derivados heterociclicos que contienen nitrogeno, metodo de preparacion y utilizacion del mismo
CL2025002505A1 (es) Compuestos derivados de pirazolopirimidina inhibidores del inflamasoma nlrp3.